The invention discloses application of CD36-mediated
sodium palmitate to promotion of CML
drug resistance through metabolic
reprogramming, and relates to the technical field of biological
medicine. The
medicine for treating the CML is screened by utilizing the CD36-EHHADH metabolic axis, and the specific method comprises the following steps: co-culturing a candidate
medicine and a CML
cell line, detecting the influence of the medicine on the key molecular expression and
cell proliferation of the CD36-EHHADH metabolic axis, and screening out the medicine with the treatment potential. According to the method for screening the medicine for treating the CML by utilizing the CD36-EHHADH metabolic axis, the candidate medicine and the CML
cell line are co-cultured, the influence of the medicine on key molecule expression and cell proliferation is detected, and the medicine with treatment potential can be rapidly screened out; according to the method, blind screening is avoided, the efficiency and success rate of new
drug research and development are improved, and more effective therapeutic
drug choices are expected to be provided for CML patients.